Anti-VEGF therapy revived by c-Met inhibition, but is c-Met the answer?

Related Articles

Anti-VEGF therapy revived by c-Met inhibition, but is c-Met the answer?

Cancer Discov. 2012 Mar;2(3):211-3

Authors: Lynn KD, Brekken RA

Abstract
A new study by Sennino and colleagues demonstrates that selective VEGF inhibition via the use of an anti-VEGF antibody is sufficient to increase invasion and metastasis in a c-Met-dependent manner. Anti-VEGF therapy induced tumor hypoxia, hypoxia-inducible factor 1?, and c-Met activation in the RIP-Tag2 model of neuroendocrine pancreatic cancer. Selective c-Met inhibition was sufficient to block these effects, providing a potential mechanism for and solution to overcome increased invasion in the face of anti-VEGF therapy.

PMID: 22585992 [PubMed - indexed for MEDLINE]

coxinhibitors c-met inhibitors